Lilly and Hims & Hers Partner to Expand Access to FDA-Approved Obesity Medicines
Eli Lilly and Company and Hims & Hers Health, Inc. have announced an agreement designed to expand patient access to two of Lilly’s obesity medicines, Zepbound (tirzepatide) and Foundayo (orforglipron). Through this collaboration, eligible patients who receive a prescription from a licensed healthcare provider on the Hims & Hers platform will be able to access these FDA-approved medicines at the same self-pay prices available to other patients. The arrangement is intended to make the process of accessing treatment more direct for people who choose to receive healthcare through a digital platform.
The agreement brings together Lilly’s pharmaceutical portfolio and Hims & Hers’ digital healthcare services. Under the arrangement, patients can begin with a consultation through the Hims & Hers platform and receive an evaluation from a licensed provider. If the provider determines that treatment is appropriate, the patient may receive a prescription for an eligible Lilly medicine. The medication can then be shipped directly to the patient’s home, allowing the consultation, prescription process and access to treatment to take place through one connected experience.
The companies said self-pay pricing through the agreement starts at $149 per month for Foundayo and $299 per month for Zepbound. These prices are intended to provide eligible patients with access to the medicines through the Hims & Hers platform without requiring them to leave the service to obtain the applicable self-pay pricing. The agreement therefore focuses on connecting patients with FDA-approved treatment options while simplifying the steps involved in accessing them.
Connecting Pharmaceutical Treatments With Digital Healthcare
The collaboration reflects an effort by both companies to make prescription obesity treatments more accessible through digital healthcare services. Hims & Hers operates a consumer-focused healthcare platform through which patients can connect with providers and receive care. Lilly brings its medicines and pharmaceutical expertise to the arrangement, creating a channel through which eligible patients can access specific FDA-approved treatments after an appropriate clinical assessment.
For patients, the process is designed to bring several stages of care together. They can start by requesting a consultation through Hims & Hers, discuss their healthcare needs with a licensed provider and receive a prescription if the provider considers a Lilly medicine suitable. The prescribed medication can then be delivered to the patient’s home. By keeping these steps within the platform, the companies aim to provide a more straightforward experience for people seeking prescription-based obesity care.
The agreement also recognizes that patients increasingly have different preferences when choosing how to access healthcare. Some people may prefer to begin their care journey through a digital platform rather than arranging every step through separate services. The partnership gives eligible Hims & Hers users another route to access Lilly medicines, while retaining the role of licensed healthcare providers in determining whether a particular treatment is appropriate.
Lilly Highlights the Importance of Reaching Patients Through Accessible Channels
Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities at Eli Lilly and Company, said the company continues to look for ways to help more people access the medicines they need. He explained that reaching patients through services they already use is an important part of that effort. The agreement with Hims & Hers is intended to provide patients with a more direct way to access FDA-approved Lilly medicines when prescribed by an appropriate healthcare provider.
Yuffa also highlighted the scale of the Hims & Hers platform and the opportunity to connect its users with Lilly’s treatments. Millions of people use Hims & Hers for healthcare services, and the collaboration creates an additional pathway for eligible patients to obtain Lilly medicines through the platform. The arrangement combines digital access with the availability of prescription treatments, while maintaining the requirement for a licensed provider to make the clinical decision.
For Lilly, the agreement represents another way to connect its obesity medicines with patients seeking care. Rather than requiring patients to navigate a separate process to access the applicable self-pay prices, the partnership is designed to make those prices available within the Hims & Hers experience. The companies are positioning the arrangement around convenience, access and the importance of ensuring that treatment is prescribed through an appropriate clinical process.
Growing Patient Interest in Digital Obesity Care
The companies noted that adults with obesity have demonstrated strong and growing interest in receiving healthcare through telehealth providers, including access to prescription medicines. Digital healthcare services offer patients a way to begin consultations and communicate with providers through online platforms. As more FDA-approved GLP-1 treatment options become available, the companies see an opportunity to connect patients who prefer digital care with established pharmaceutical treatments.
The availability of a broader range of FDA-approved obesity medicines is an important part of this development. Lilly’s portfolio includes Zepbound, an injectable treatment, and Foundayo, its daily oral medicine. These medicines provide different treatment formats for eligible patients, subject to clinical assessment and prescribing decisions. Through the agreement, Hims & Hers users will have a platform-based route to access either medicine when a licensed provider determines that it is appropriate.
The partnership is intended to serve people who choose to seek care through one of the world’s largest digital health platforms. By combining Hims & Hers’ existing patient-facing services with Lilly’s FDA-approved medicines, the companies aim to reduce some of the steps involved in accessing treatment. The arrangement also gives patients an opportunity to discuss their needs with a provider before a prescription is issued, rather than treating access to medication as a process separate from clinical care.
Hims & Hers Emphasizes the Value of the Partnership
Andrew Dudum, co-founder and CEO of Hims & Hers, described Lilly as one of the most innovative pharmaceutical companies in history and expressed pride in the platform’s role in helping more people access its medicines. He said the collaboration is intended to expand access to FDA-approved Lilly treatments for people with obesity through a more connected digital healthcare experience.
Dudum also emphasized the broader importance of cooperation between pharmaceutical companies and digital healthcare providers. In his comments, he highlighted how collaboration can help companies reach more customers and make healthcare services more accessible. The agreement reflects the view that pharmaceutical innovation and digital health platforms can work together to provide patients with more direct access to prescribed treatments.
For Hims & Hers, the agreement adds a pathway for eligible patients to access two specific Lilly medicines through its existing platform. The company already supports customers through different stages of their healthcare journeys, including initial questions, clinical consultations, treatment planning and follow-up care. The addition of access to Zepbound and Foundayo strengthens the range of treatment options that may be available to patients whose providers determine that these medicines are suitable.
Ongoing Care and Support Through the Hims & Hers Platform
Hims & Hers describes its healthcare model as supporting customers throughout their care journey, rather than focusing only on the initial consultation or prescription. Its technology platform supports provider outreach, follow-up care and treatment planning. This structure is relevant to the obesity care offering because patients may require continued communication and support as they move through their treatment journey.
Weight loss patients using Hims & Hers receive a membership experience that includes 24/7 access to a care team. The offering also includes nutrition guidance, regular clinical check-ins and access to the Hims & Hers Weight Loss community. These services are designed to provide ongoing support alongside the clinical treatment process and help patients remain connected to their care resources.
The platform’s approach combines access to healthcare providers with additional services intended to support patients beyond receiving medication. Nutrition guidance and regular clinical check-ins are included as part of the weight loss membership experience described by the company. The availability of these services provides a broader care framework for patients using the platform, while clinical decisions about prescriptions remain with licensed providers.
The agreement with Lilly fits into this existing model by adding access to the company’s FDA-approved obesity medicines. Patients can use the platform to begin a consultation, receive clinical guidance and, if appropriate, obtain a prescription. The arrangement is intended to connect access to medication with the wider support services already offered through Hims & Hers.
Companies Emphasize Independent Clinical Decision-Making
An important element of the agreement is the companies’ commitment to protecting independent clinical decision-making. Under the arrangement, providers using the Hims & Hers platform will continue to determine which treatment is appropriate for each patient. The partnership does not remove the provider’s responsibility to assess a patient’s circumstances and make an independent prescribing decision.
This commitment is significant because the agreement involves access to specific medicines through a commercial partnership. The companies have stated that treatment decisions will remain with the healthcare providers, who must determine whether a particular medicine is suitable. Patients will therefore need to complete the consultation process and meet the provider’s clinical requirements before receiving a prescription.
The arrangement also makes clear that access to a medicine through the platform does not mean every patient will automatically receive it. A prescription depends on the provider’s assessment and clinical judgment. This distinction keeps the consultation and prescribing process central to the agreement, rather than making the medicines available without an appropriate healthcare evaluation.
By emphasizing independent clinical decisions, Lilly and Hims & Hers are seeking to establish that the partnership is intended to expand access without changing the provider’s role. The provider remains responsible for determining the appropriate treatment for an individual patient. The companies have committed to maintaining that independence as part of their collaboration.
Hims & Hers Reaffirms Its Position on Compounded Copies of Lilly Medicines
The companies also addressed the issue of compounded versions of Lilly’s GLP-1 medicines. Hims & Hers stated that it has never offered access to compounded copies of Lilly’s GLP-1 medicines and has committed not to offer them in the future. This position is included as part of the agreement and distinguishes the collaboration’s focus on access to FDA-approved Lilly medicines.
The agreement is centered on Zepbound and Foundayo, with access provided through prescriptions issued by licensed providers when clinically appropriate. The companies’ stated commitment regarding compounded copies is intended to clarify the nature of the medicines being made available through the partnership. The focus is on connecting eligible patients with Lilly’s FDA-approved products rather than offering compounded copies of those medicines.
The companies have also linked this commitment with their position on independent clinical decision-making. The provider’s responsibility to determine appropriate treatment remains in place, and the agreement does not change that principle. Together, these commitments form part of the framework under which the companies intend to expand access through the Hims & Hers platform.
Self-Pay Pricing and Home Delivery
Pricing is another central component of the announcement. According to the companies, eligible patients can access self-pay prices starting at $149 per month for Foundayo and $299 per month for Zepbound through the agreement. These are the same self-pay prices available to any patient, and eligible patients will be able to access them without leaving the Hims & Hers platform.
The pricing structure is intended to make the process more direct for patients who choose to use Hims & Hers for their care. Instead of moving between separate services to complete the consultation and access the applicable pricing, patients can use the platform for the consultation, prescription process and access to the medicine. The medication can then be shipped directly to the patient’s home.
The companies’ announcement describes these amounts as starting prices for self-pay access. Patients should review the applicable terms and confirm their eligibility, treatment suitability and pricing details through the platform. The provider’s clinical assessment remains necessary before a prescription can be issued, and the availability of a particular medicine does not guarantee that it will be prescribed to every patient.
A Collaboration Focused on Expanding Access to Obesity Treatment
The agreement between Eli Lilly and Hims & Hers brings together two companies operating in different parts of the healthcare ecosystem. Lilly contributes its FDA-approved obesity medicines, while Hims & Hers provides a digital platform through which patients can connect with licensed providers and access ongoing healthcare support. The collaboration is designed to create a more connected route for eligible patients seeking prescription-based obesity care.
The partnership also reflects the growing role of digital healthcare platforms in connecting patients with medical services. Through the Hims & Hers platform, patients can begin consultations, receive clinical evaluations and access follow-up support. With the addition of Zepbound and Foundayo, eligible patients may have another way to obtain Lilly medicines through a service they already use.
Ultimately, the companies’ stated objective is to expand access while preserving the importance of clinical judgment. The agreement provides access to self-pay pricing starting at $149 per month for Foundayo and $299 per month for Zepbound, with home delivery available through the platform following an appropriate prescription. Hims & Hers will continue to provide its broader weight loss membership services, while licensed providers retain responsibility for deciding which treatment is right for each patient.
Through this collaboration, Lilly and Hims & Hers aim to make FDA-approved obesity medicines more accessible to patients who prefer digital healthcare services. The agreement combines pharmaceutical treatments, online consultations, ongoing patient support and home delivery within one platform-based experience. Both companies have emphasized that expanding access must go hand in hand with appropriate prescribing and independent clinical decision-making.
Source link: https://news.hims.com/
